BeOne Medicines Ltd. (688235.SH) has announced that its wholly-owned subsidiary, BeOne Medicines I GmbH (a company registered in Switzerland, referred to as "BeOne Switzerland"), intends to participate in the Series A financing of Bravera Bio, Inc. ("Bravera") alongside 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences," together with 667 referred to as the "Baker Bros Entities") as well as other investors.
The financing will be completed in three tranches, comprising one initial closing and two subsequent closings. The two subsequent closings are contingent upon whether specified milestones and closing conditions are met or waived.
BeOne Switzerland is expected to invest a total of USD 19.5 million in cash and will convert its USD 500,000 interest held under a future simple agreement for future equity ("SAFE") into Series A preferred shares of Bravera.
Upon completion of this transaction, BeOne Switzerland will hold a 9.477% stake in Bravera. The co-investment between BeOne Switzerland and related parties is based on the company's overall development strategy and business needs.
The source of funds for this transaction is BeOne Switzerland's own capital, and the transaction follows the principle of fair dealing with fair and reasonable pricing. This transaction will not have a material adverse impact on the company's main business, going-concern capability, or asset condition, nor will it harm the overall interests of the company and its shareholders.
Comments